Literature DB >> 29117483

A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism.

Eric M Gale1, Hsiao-Ying Wey1, Ian Ramsay1, Yi-Fen Yen1, David E Sosnovik1, Peter Caravan1.   

Abstract

Purpose To compare intravascular contrast enhancement produced by the manganese-based magnetic resonance (MR) imaging contrast agent manganese-N-picolyl-N,N',N'-trans-1,2-cyclohexenediaminetriacetate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics, and metabolism of Mn-PyC3A. Materials and Methods Contrast material-enhanced MR angiography was performed in baboons (Papio anubis; n = 4) by using Mn-PyC3A and Gd-DTPA. Dynamic imaging was performed for 60 minutes following Mn-PyC3A injection to monitor distribution and elimination. Serial blood sampling was performed to quantify manganese and gadolinium plasma clearance by using inductively coupled plasma mass spectrometry and to characterize Mn-PyC3A metabolism by using high-performance liquid chromatography. Intravascular contrast enhancement in the abdominal aorta and brachiocephalic artery was quantified by measuring contrast-to-noise ratios (CNRs) versus muscle at 9 seconds following Mn-PyC3A or Gd-DTPA injection. Plasma pharmacokinetics were modeled with a biexponential function, and data were compared with a paired t test. Results Aorta versus muscle CNR (mean ± standard deviation) with Mn-PyC3A and Gd-DTPA was 476 ± 77 and 538 ± 120, respectively (P = .11). Brachiocephalic artery versus muscle CNR was 524 ± 55 versus 518 ± 140, respectively (P = .95). Mn-PyC3A was eliminated via renal and hepatobiliary excretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes, 20.2 ± 3.1 and 17.0 ± 2.4, respectively; P = .23). High-performance liquid chromatography revealed no evidence of Mn-PyC3A biotransformation. Conclusion Mn-PyC3A enables contrast-enhanced MR angiography with comparable contrast enhancement to gadolinium-based agents and may overcome concerns regarding gadolinium-associated toxicity and retention. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29117483      PMCID: PMC5831267          DOI: 10.1148/radiol.2017170977

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  29 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

Review 2.  Dynamic contrast-enhanced breast MR imaging.

Authors:  Marianne Moon; Daniel Cornfeld; Jeffrey Weinreb
Journal:  Magn Reson Imaging Clin N Am       Date:  2009-05       Impact factor: 2.266

Review 3.  Use of contrast media in neuroimaging.

Authors:  Marco Essig; Julien Dinkel; Juan E Gutierrez
Journal:  Magn Reson Imaging Clin N Am       Date:  2012-09-26       Impact factor: 2.266

4.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

5.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

6.  High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.

Authors:  Donna R Roberts; Scott M Lindhorst; Cynthia T Welsh; Kenneth R Maravilla; Mary N Herring; K Adam Braun; Bruce H Thiers; W Clay Davis
Journal:  Invest Radiol       Date:  2016-05       Impact factor: 6.016

7.  Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases.

Authors:  Richard C Semelka; Clayton W Commander; Michael Jay; Lauren M B Burke; Miguel Ramalho
Journal:  Invest Radiol       Date:  2016-10       Impact factor: 6.016

8.  Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.

Authors:  B Hamm; T J Vogl; G Branding; B Schnell; M Taupitz; K J Wolf; J Lissner
Journal:  Radiology       Date:  1992-01       Impact factor: 11.105

9.  A Manganese Alternative to Gadolinium for MRI Contrast.

Authors:  Eric M Gale; Iliyana P Atanasova; Francesco Blasi; Ilknur Ay; Peter Caravan
Journal:  J Am Chem Soc       Date:  2015-12-04       Impact factor: 15.419

10.  Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2.

Authors:  Y Ni; C Petré; H Bosmans; Y Miao; D Grant; A L Baert; G Marchal
Journal:  Acta Radiol       Date:  1997-07       Impact factor: 1.701

View more
  21 in total

1.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

2.  Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging of the Central Nervous System.

Authors:  Eric M Gale; Peter Caravan
Journal:  ACS Chem Neurosci       Date:  2018-02-12       Impact factor: 4.418

3.  Molecular Magnetic Resonance Imaging with Gd(III)-Based Contrast Agents: Challenges and Key Advances.

Authors:  Hao Li; Thomas J Meade
Journal:  J Am Chem Soc       Date:  2019-10-17       Impact factor: 15.419

4.  Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex.

Authors:  Huan Wang; Veronica Clavijo Jordan; Ian A Ramsay; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  J Am Chem Soc       Date:  2019-03-28       Impact factor: 15.419

5.  Amphiphilic DTPA Multimer Assembled on Icosahedral Closo-Borane Motif as High-Performance MRI Blood Pool Contrast Agent.

Authors:  Lalit N Goswami; Shatadru Chakravarty; Quan-Yu Cai; Erik M Shapiro; M Frederick Hawthorne; Lixin Ma
Journal:  ACS Appl Bio Mater       Date:  2021-08-25

Review 6.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

7.  Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.

Authors:  Junfeng Wang; Huan Wang; Ian A Ramsay; Derek J Erstad; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  J Med Chem       Date:  2018-09-25       Impact factor: 7.446

8.  Manganese(II)-Based Responsive Contrast Agent Detects Glucose-Stimulated Zinc Secretion from the Mouse Pancreas and Prostate by MRI.

Authors:  Sara Chirayil; Veronica Clavijo Jordan; André F Martins; Namini Paranawithana; S James Ratnakar; A Dean Sherry
Journal:  Inorg Chem       Date:  2021-01-28       Impact factor: 5.165

9.  Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A.

Authors:  Iris Yuwen Zhou; Ian A Ramsay; Ilknur Ay; Pamela Pantazopoulos; Nicholas J Rotile; Alison Wong; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2021-04-01       Impact factor: 10.065

10.  Biventricular Strain Imaging with Cardiac MRI in Genotyped and Histology Validated Amyloid Cardiomyopathy.

Authors:  Abhinay Reddy; Vasvi Singh; Badri Karthikeyan; Leyi Jiang; Silva Kristo; Sharma Kattel; Ram Amuthan; Saraswati Pokharel; Umesh C Sharma
Journal:  Cardiogenetics       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.